Effects of Inclisiran in Patients With ASCVD

Dr. R. Scott Wright, a Cardiologist from Mayo Clinic in Rochester, MN, shares insights from his article appearing in the August 2024 issue of Mayo Clinic Proceedings, where he found twice-yearly inclisiran (after initial and 3-month doses) injection was well tolerated and provided significant, consistent LDL-C reductions for up to 18 months in participants with atherosclerotic cardiovascular disease, independent of key patient characteristics. Available at: mayocl.in/3VfLGVX